Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | Gaps in YOBC therapeutics targeting genomic mutations

Alina Basnet • 14 Feb 2025
GU Cancers 2025
Bladder Cancer Genitourinary Cancer

Alina Basnet, MD, MBBS, SUNY Upstate Medical University, Syracuse, NY, explains the lack of currently emerging therapeutic approaches to specifically target patients with young-onset bladder cancer (YOBC). Whilst genomic differences have been identified between patients with early YOBC and clinically advanced YOBC, more studies could highlight targetable mutations out with the potentially targetable MTAP and PTEN mutations. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Alina Basnet

Genomic differences in older- vs younger-onset bladder cancer
1:43
Genomic differences in older- vs younger-onset bladder cancer
Alina Basnet • 14 Feb 2025
Genomic profiling of CAUBC in younger versus older patients
2:07
Genomic profiling of CAUBC in younger versus older patients
Alina Basnet • 13 Feb 2025

Related Videos

Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
1:55
Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
Sarah Howlett • 26 Oct 2026
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
2:20
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
Jens Bedke • 26 Oct 2026
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
2:24
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
Jens Bedke • 26 Oct 2026
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
2:58
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
Jens Bedke • 26 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals